Large pharmaceutical companies have been cutting back on their in-house Alzheimer’s research and development. The lack of progress in the fight against Alzheimer’s likely has more to do with the world of finance than the world of biology. Pharmaceutical companies are not able to pursue promising research directions due to business model considerations of profit potential and investment risk. (being patient)
Using sound and light: a new way to perform drug-based studies?
www.scienceandtechnologyresearchnews.com
An international team has developed an innovative new way to hold samples using sound while they are gently imaged using light. The normal way to immobilize an object would be to use a gel, but introducing drugs to the sample could be slow and unpredictable using this method. Using sound and light is a new way to perform drug-based studies. (Science & Technology Research News)
New FDA Guidance. February 2019
The purpose of this guidance is to assist sponsors of drug and biological products for the treatment or prevention of rare diseases in conducting more efficient and successful drug development programs. Although the statutory requirements for marketing approval for drugs to treat rare and common diseases are the same and issues discussed here are encountered in other drug development programs, these issues are frequently more difficult to address in the context of a rare disease. (fda.gov)
Freelance writer positions available
“Clinical Research Currents” is looking for individuals who would like to write clinical research-related articles for our newsletter and website. This could involve: identify the topic, conduct interviews, write up, and publish. We can help you by offering ideas for articles, or helping with interview questions, as you wish. Contact: Read more
Why do Phase 3 trials fail?
Drug development is marked by high attrition rates, and the third phase is the most critical. A recent commentary reviewed high profile cases of failed drugs to identify the sources of late-stage failure, and classified the causes of drug failure into avoidable and unavoidable errors. Avoidable errors arise from a lack of scientific rigour, while unavoidable errors arise due to a deficiency in scientific knowledge. (Medical News Bulletin)
Could we treat age-related diseases with “senolytics”?
University of Texas Health San Antonio researchers became the first to publish results of the treatment of an age-related disease, idiopathic pulmonary fibrosis (IPF), in human patients with drugs called senolytics. Previously, no published data demonstrated that drugs targeting cellular senescence could be safely given to adults or that they might be used to treat diseases of aging. (ScienceDaily)
Infographic: Women in clinical research through the years
Women have seen deficits and gains in their attempts to be included in clinical research, but as 2019 approaches equality seems forthcoming. (Outsourcing-Pharma.com)
Nearly 300 cell and gene therapies are in development
The new field of cell and gene therapy is part of a new era of medicine, regenerative medicine, which is transforming treatment options for some patients. Today, there are nearly 300 novel cell and gene therapies in development for a range of diseases and conditions. (Cision PR Newswire)
Conservatism of pharmaceutical industry a barrier to AI and machine learning
www.clinicalinformaticsnews.com
Senior Director at Cytel believes that artificial intelligence and machine learning are going to change the clinical development paradigm, but there are challenges to overcome before AI and machine learning will be useful in clinical trials. Challenges include availability of data and the opinions of pharmaceutical companies and regulators. (Clinical Informatics News)
AI companies may be the “Deux ex Machina” of pharmaceutical R&D
“Although pharmaceutical companies spend over $172 billion on research and development annually, over 90% of molecules discovered using traditional techniques fail in human clinical trials.” AI may be the “Deux ex Machina” in the field of pharmaceutical R&D. Deep Knowledge Analytics publishes their list of AI companies that are solely dedicated to scientific R&D. (Forbes)
- 1
- 2
- 3
- …
- 9
- Next Page »